Terms: = Pancreatic cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Clinical Outcome
12 results:
1. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in k-ras-driven cancer.
Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
[TBL] [Abstract] [Full Text] [Related]
2. Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro.
Yamaguchi M; Osuka S; Weitzmann MN; El-Rayes BF; Shoji M; Murata T
Int J Oncol; 2016 May; 48(5):1955-64. PubMed ID: 26935290
[TBL] [Abstract] [Full Text] [Related]
3. Combining clinicopathological predictors and molecular biomarkers in the oncogenic k-ras/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract] [Full Text] [Related]
4. pancreatic cancer-improved care achievable.
Buanes TA
World J Gastroenterol; 2014 Aug; 20(30):10405-18. PubMed ID: 25132756
[TBL] [Abstract] [Full Text] [Related]
5. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits k-ras through ERK, Akt and survivin in pancreatic cancer cells.
Rabi T; Venkatanarashiman M
Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674
[TBL] [Abstract] [Full Text] [Related]
6. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.
Chang DZ; Ma Y; Ji B; Wang H; Deng D; Liu Y; Abbruzzese JL; Liu YJ; Logsdon CD; Hwu P
Clin Cancer Res; 2011 Nov; 17(22):7015-23. PubMed ID: 21976550
[TBL] [Abstract] [Full Text] [Related]
7. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis.
Sedivy R; Kalipciyan M; Mazal PR; Wolf B; Wrba F; Karner-Hanusch J; Mühlbacher F; Mader RM
Cancer Detect Prev; 2005; 29(1):8-14. PubMed ID: 15734212
[TBL] [Abstract] [Full Text] [Related]
8. Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases.
McCarthy DM; Hruban RH; Argani P; Howe JR; Conlon KC; Brennan MF; Zahurak M; Wilentz RE; Cameron JL; Yeo CJ; Kern SE; Klimstra DS
Mod Pathol; 2003 Mar; 16(3):272-8. PubMed ID: 12640108
[TBL] [Abstract] [Full Text] [Related]
9. A modified mutagenic PCR-RFLP method for k-ras codon 12 and 13 mutations detection in NSCLC patients.
Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
[TBL] [Abstract] [Full Text] [Related]
10. k-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.
Castells A; Puig P; Móra J; Boadas J; Boix L; Urgell E; Solé M; Capellà G; Lluís F; Fernández-Cruz L; Navarro S; Farré A
J Clin Oncol; 1999 Feb; 17(2):578-84. PubMed ID: 10080602
[TBL] [Abstract] [Full Text] [Related]
11. pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma.
Tamagawa E; Ueda M; Takahashi S; Sugano K; Uematsu S; Mukai M; Ogata Y; Kitajima M
Clin Cancer Res; 1997 Nov; 3(11):2143-9. PubMed ID: 9815608
[TBL] [Abstract] [Full Text] [Related]
12. A prospective study of k-ras mutations in the plasma of pancreatic cancer patients.
Mulcahy HE; Lyautey J; Lederrey C; qi Chen X; Anker P; Alstead EM; Ballinger A; Farthing MJ; Stroun M
Clin Cancer Res; 1998 Feb; 4(2):271-5. PubMed ID: 9516910
[TBL] [Abstract] [Full Text] [Related]
